Journal article

Prostate-specific membrane antigen PET: Clinical utility in prostate cancer, normal patterns, pearls, and pitfalls

MS Hofman, RJ Hicks, T Maurer, M Eiber

Radiographics | RADIOLOGICAL SOC NORTH AMERICA | Published : 2018

Abstract

Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is overexpressed in prostate cancer. Radiolabeled small molecules that bind with high affinity to its active extracellular center have emerged as a potential new diagnostic standard of reference for prostate cancer, resulting in images with extraordinary tumor-to-background contrast. Currently, gallium 68 (68Ga)-PSMA-11 (or HBED-PSMA) is the most widely used radiotracer for PSMA positron emission tomography (PET)/computed tomography (CT) or PSMA PET/magnetic resonance (MR) imaging. Evolving evidence demonstrates superior sensitivity and specificity of PSMA PET compared to conventional imaging, with frequent identi..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Health and Medical Research Council


Funding Acknowledgements

M.S.H. supported by a Movember Clinical Trials Award from the Prostate Cancer Foundation of Australia research program and a Clinical Fellowship Award from the Peter MacCallum Cancer Foundation. R.J.H. supported by a National Health and Medical Research Council of Australia Practitioner Fellowship. M.E. supported by SFB 824 (DFG Sonderforschungsbereich 824, Project B11) from the Deutsche Forschungsgemeinschaft.